Skip to main content
SpringerLink
Log in

Cytomegalovirus Reactivation in Patients Infected with HIV

The Use of Polymerase Chain Reaction in Prediction and Management

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Patients with HIV are living longer now than in the past, and with a better quality of life. During the advanced stages of HIV infection patients are at risk of cytomegalovirus (CMV) reactivation and subsequently CMV disease. It is important to review the evidence on whether CMV reactivation leads to CMV disease and what the best methods are for detecting such a reactivation. CMV polymerase chain reaction (PCR) can be used qualitatively to predict CMV disease and quantitatively to predict a general increase in mortality. CMV PCR can also be used to direct either prophylaxis or pre-emptive therapy to those most at risk of CMV disease. CMV PCR should be an integral part of the decision-making process when treating both new patients with CMV retinitis and those with disease reactivation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zurlo JJ, O’Neill D, Polis MA, et al. Lack of clinical utility of cytomegalovirus blood and urine cultures in patients with HIV infection. Ann Intern Med 1993; 118(1): 12–7

    PubMed  CAS  Google Scholar 

  2. Salmon D, Lacassin F, Harzic M, et al. Predictive value of cytomegalovirus viraemia for the occurrence of CMV organ involvement in AIDS. J Med Virol 1990; 32(3): 160–3

    Article  PubMed  CAS  Google Scholar 

  3. Rasmussen L, Morris S, Zipeto D, et al. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J Infect Dis 1995; 171(1): 177–82

    Article  PubMed  CAS  Google Scholar 

  4. Spector SA, Merrill R, Wolf D, et al. Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol 1992; 30(9): 2359–65

    PubMed  CAS  Google Scholar 

  5. Bek B, Boeckh M, Lepenies J, et al. High-level sensitivity of quantitative pp65 cytomegalovirus (CMV) antigenaemia assay for diagnosis of CMV disease in AIDS patients and follow-up. J Clin Microbiol 1996; 34(2): 457–9

    PubMed  CAS  Google Scholar 

  6. Reynes J, Montes B, Atoni N, et al. Significance of cytomegalovirus (CMV)-pp65 antigenaemia in the diagnosis of CMV disease in human immunodeficiency virus-infected patients. J Med Virol 1996; 49: 195–8

    Article  PubMed  CAS  Google Scholar 

  7. Bowen EF, Sabin CA, Wilson P, et al. CMV DNAemia detected by PCR identifies a group of HIV positive patients at high risk of CMV disease. AIDS 1997; 11: 889–93

    Article  PubMed  CAS  Google Scholar 

  8. Shinkai M, Bozzette SA, Powderely W, et al. Utility of urine and leukocyte culture and plasma DNA PCR for identification of HIV patients at risk for human CMV disease. J Infect Dis 1997; 175: 502–8

    Article  Google Scholar 

  9. Dodt KK, Hoy Jacobsen P, Hoffman B. Development of CMV disease may be predicted in HIV-infected patients by CMV PCR and the antigenaemia test. AIDS 1997; 11: F21–8

    Article  PubMed  CAS  Google Scholar 

  10. Walmsley S, O’Rourke, Mortimer C, et al. Predictive value of CMV antigenaemia and digene capture assay for CMV disease in HIV infected patients. Clin Infect Dis 1998; 27: 573–81

    Article  PubMed  CAS  Google Scholar 

  11. Bowen EF, Sabin CA, Wilson P, et al. Cytomegalovirus Retinitis in AIDS patients: influence of CMV load on response to ganciclovir, time to recurrence and survival. AIDS 1996; 10: 1515–20

    Article  PubMed  CAS  Google Scholar 

  12. Spector SA, Wong R, Hsia K, et al. Plasma CMV DNA load predicts CMV disease and Survival in AIDS patients. J Clin Invest 1998; 101(2): 497–502

    Article  PubMed  CAS  Google Scholar 

  13. Boivin G, Handfield J, Toma E, et al. Evaluation of the AMPLICOR CMV test with specimens from HIV infected subjects. J Clin Microbiol 1998; 36(9): 2509–13

    PubMed  CAS  Google Scholar 

  14. Rubin RH. Preemptive therapy in immunocompromised hosts [editorial]. N Engl J Med 1991; 324(15): 1057–9

    Article  PubMed  CAS  Google Scholar 

  15. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173–8

    PubMed  CAS  Google Scholar 

  16. Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991; 324(15): 1005–11

    Article  PubMed  CAS  Google Scholar 

  17. Spector SA, McKinley GF, Lalezari JP, Roche Cooperative Oral Ganciclovir Study Group et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med 1996; 334(23): 1491–7

    Article  PubMed  CAS  Google Scholar 

  18. Feinberg JE, Hurwitz S, Cooper D, et al. A randomised double blind trial of valaciclovir prophylaxis for CMV disease in patients with AIDS. J Infect Dis 1998; 177: 48–56

    Article  PubMed  CAS  Google Scholar 

  19. Griffiths PD, Feinberg JE, Sabin C, et al. The effect of valaciclovir on CMV viremia and viruria detected by PCR in patients with advanced HIV disease. J Infect Dis 1998; 177: 57–64

    Article  PubMed  CAS  Google Scholar 

  20. Grzywacz M, Bowen EF, Wilson P, et al. Response of asymptomatic viraemia to oral ganciclovir 3g/day or 6g/day. J Med Virol. In press

  21. Bowen EF.The natural history of CMV infection in the HIV infected host [PhD thesis]. London: London University, 1997

  22. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with HIV infection. N Engl J Med 1998; 338(13): 853–60

    Article  PubMed  Google Scholar 

  23. Deayton J, Wilson P, Johnson MA, et al. HAART can completely suppress asymptomatic CMV viremia in the absence of specific anti-CMV therapy [abstract]. Interscience Congress Anti-microbial Agents and Chemotherapy (ICAAC) 1998; I-268

  24. Bowen EF, Johnson MA, Wilson P, et al. Cytomegalovirus polymerase chain reaction viraemia in patients receiving maintenance therapy for retinitis. AIDS 1998; 12: 605–11

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St Helier Hospital, Wrythe Lane, Carshalton, Surrey, SM5 1AA, England

    E. Frances Bowen

Authors
  1. E. Frances Bowen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Frances Bowen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frances Bowen, E. Cytomegalovirus Reactivation in Patients Infected with HIV. Drugs 57, 735–741 (1999). https://doi.org/10.2165/00003495-199957050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199957050-00006

Keywords

Search

Navigation